Dry Eye Treatment Devices Market - By Technology (Broadband Light (BBL), Intense Pulsed Light (IPL), Meibomian Gland Expression (MGX), Combination (MGX+IPL)), By End-use (Hospitals, Ophthalmic Clinics), & Forecast, 2023 – 2032

Dry Eye Treatment Devices Market Size

Dry Eye Treatment Devices Market size was valued at over USD 260 million in 2022 and is anticipated to grow at a CAGR of 8.4% between 2023 and 2032. This incremental growth rate is owing to increasing prevalence of dry eye disease coupled with technological advancements in dry eye treatment devices. Increasing number of contact lens wearers associated with growing usage of visual display terminals is anticipated to drive the dry eye treatment devices industry expansion.
 

The dry eye treatment devices market is experiencing a significant growth in recent years due to the increasing prevalence of dry eye syndrome, aging population, rising digital device usage, and the growing awareness of its impact on ocular health. Technological advancements are leading to the development of innovative dry eye treatment devices, to improve the effectiveness of treatments. Additionally, increasing awareness among patients and healthcare professionals about the importance of timely and effective dry eye treatment has led to greater adoption of these devices. The dry eye treatment devices industry is poised for continued growth as the prevalence of dry eye syndrome rises, and patients seek effective and convenient solutions to manage their symptoms. Therefore, the dry eye treatment devices industry is witnessing substantial growth and innovation, driven by the demand for better diagnosis and treatment of ocular ailments and technological advancements that focus on patient-centric treatments are expected to drive the dry eye treatment devices market growth.
 

Dry eye treatment devices are medical devices designed to alleviate the symptoms and address the underlying causes of dry eye syndrome. Dry eye treatment devices employ various technologies and approaches to improve tear production, enhance tear quality, and provide relief from dry eye symptoms.
 

However, the presence of contraindications can pose a potential challenge to the growth of the dry eye treatment devices market. Contraindications refer to specific circumstances or conditions in which a particular treatment or device should not be used due to potential risks or adverse effects on the patient. For instance, in the case of intense pulsed light (IPL) devices for dry eye treatment, there are certain contraindications that may limit their widespread adoption and market growth. IPL treatment involves the use of light energy, that can cause discomfort or adverse reactions in individuals with sensitive or easily irritated skin. Certain eye conditions or diseases, such as glaucoma, cataracts, and retinal disorders, are contraindicated for IPL treatment. The intense light energy emitted by IPL devices can potentially aggravate or worsen these pre-existing eye conditions.
 

Certain medications or medical conditions, such as photosensitivity disorders, can contraindicate the use of IPL devices. Patients with a history of adverse reactions to light-based treatments or those taking medications that increase sensitivity to light are advised against IPL treatment. Therefore, the aforementioned factors and contraindications can limit the eligibility of certain patients for the usage of dry eye treatment devices, thereby rendering a negative impact over the market growth.
 

COVID-19 Impact

The recent outbreak of COVID-19 had negatively influenced the dry eye treatment devices industry revenue, specifically during the initial phase of 2020. The coronavirus outbreak proliferated the disease burden and hampered several global businesses including the healthcare sector, during the pandemic phase. These conditions severely impacted the dry eye treatment devices market growth. Several hospitals and healthcare facilities globally experienced a significant decline in patient visits for diagnosis and treatment of dry eye syndrome and other related ophthalmic conditions. The COVID-19 pandemic has reduced visits to healthcare facilities, causing medical services in several countries to be delayed, including surgical procedures. The pandemic has disrupted global supply chains, causing delays in the production, delivery, and distribution of dry eye treatment devices.
 

Lockdown measures, travel restrictions, and workforce limitations have impacted the ability of manufacturers to meet demand, resulting in supply shortages and reduced market growth. The COVID-19 pandemic has caused a decline in patient visits to healthcare facilities, including eye clinics and ophthalmology practices. This decrease in patient visits and delayed treatment has directly affected the demand for dry eye treatment devices. This limited access to healthcare and reduced in-person consultations have impacted the adoption and utilization of dry eye treatment devices. Thus, the COVID-19 pandemic had a negative impact on dry eye treatment devices market during 2020 which gained impetus in the later stages during 2021. As the situation evolves, as well as increased procedural volume, the dry eye treatment devices industry is expected to recover gradually to aid market growth in the approaching years.
 

Dry Eye Treatment Devices Market Trends

Increasing prevalence of dry eye disease is anticipated to drive the market growth. Dry eye disease is a common condition that affects a significant number of individuals worldwide. For instance, according to the American Academy of Ophthalmology data, in 2022, around 344 million people worldwide were suffering from dry eye disease and is expected to increase among adult population. Dry eye treatment devices aid in symptoms associated with dry eye disease, such as dryness, burning sensation, redness, itching, as well as restore tear functions among prevalent population thereby augmenting the market growth. Geriatric population are at a higher risk of dry eye syndrome as tear production and quality tend to decline with age, driving the demand for dry eye treatment devices.
 

The widespread use of digital devices, such as smartphones, computers, and tablets, has become an integral part of modern life. Prolonged screen time and decreased blink rate during device use contribute to the development of dry eye symptoms. With the increasing reliance on digital devices across all age groups, the prevalence of dry eye disease is likely to rise, boosting the demand for treatment devices. Additionally, awareness about dry eye disease and its impact on ocular health has been steadily increasing. Individuals are seeking medical attention and diagnosis for their dry eye symptoms, leading to a higher prevalence rate. Improved diagnostic tools and techniques have contributed to better identification and diagnosis of dry eye disease, further driving the demand for treatment devices. The dry eye treatment devices market has witnessed significant advancements in technology, leading to more effective and innovative treatment options.
 

Dry Eye Treatment Devices Market Analysis

Based on technology, the dry eye treatment devices market is segmented as broadband light (BBL), intense pulsed light (IPL), meibomian gland expression (MGX) and combination (MGX+IPL). The meibomian gland expression (MGX) dominated the market accounting over 41% market share in 2022. Meibomian gland expression (MGX) is a technology used to address meibomian gland dysfunction (MGD), which is a common underlying cause of dry eye disease. For instance, according to the Dry Eye Directory, in 2020, around 1 billion people globally were suffering from meibomian gland dysfunction accounting around 86% of the total population suffering from dry eye disease. Meibomian glands are responsible for producing the oily layer of the tear film, which helps prevent evaporation of tears and maintain tear stability. Dysfunction or blockage of these glands leads to decreased tear quality. Meibomian gland expression helps to unclog the blocked glands and restore the flow of healthy lipids, improving tear quality and reducing tear evaporation.
 

MGX promotes more stable tears, reducing dryness, irritation, and fluctuations in vision associated with dry eye disease. Regular and proactive use of Meibomian gland expression can help prevent the progression of meibomian gland dysfunction and associated dry eye symptoms. By maintaining the health and function of the meibomian glands, MGX can help prevent future blockages and minimize the risk of developing severe dry eye disease. Therefore, owing to several benefits offered by meibomian gland expression (MGX), the market is estimated to witness a significant growth in the coming years.
 

Based on end-use, the dry eye treatment devices market is segmented as hospitals, ophthalmic clinics and others. The hospitals segment held a dominant market share and accounted for around USD 124 million in 2022. Hospitals, have a range of diagnostic equipment’s and tools to caters to a wide range of patients suffering from dry eye diseases and other related co-morbidities. Hospitals often have dedicated ophthalmology diagnostic departments where patients can access specialized care for dry eye disease. These facilities are equipped with advanced diagnostic tools and treatment options, including dry eye treatment devices, to provide comprehensive management for patients with more severe or complex cases. Hospitals have expert ophthalmologists and eye care specialists that can recommend and administer appropriate dry eye treatment devices as part of a comprehensive treatment plan, ensuring optimal patient care.
 

Hospitals offer a multidisciplinary approach to patient care, allowing for collaboration between various healthcare professionals. This integration can be particularly beneficial for individuals with underlying systemic conditions or comorbidities that contribute to dry eye disease. The availability of dry eye treatment devices in hospitals enables coordinated care and the integration of dry eye management with other medical treatments if necessary. Hospitals are integrated with advance state-of-the-art medical equipment and technologies, including dry eye treatment devices such as intense pulsed light (IPL), meibomian gland expression (MGX), or combination therapies to provide patients with optimal treatment options. The availability of advanced diagnostic tools, expertise, and multidisciplinary collaboration in hospitals contribute to improved patient outcomes and drive the demand for dry eye treatment devices in these settings.
 

North America region held a dominant share in the global dry eye treatment devices market and was valued at USD 95 million in 2022. This high market share is ascribed to a variety of factors, including the presence of significant industry players, an increase in the number of patients suffering from dry eye disease diseases, an expanding elderly population, among others. Factors such as aging demographics, extensive use of digital devices, and environmental conditions contribute to the high prevalence of dry eye in the region. For instance, according to the American Academy of Ophthalmology data, in 2022, around 20 million Americans were estimated to suffer from dry eye disease. As a result, the region is witnessing a growing demand for effective treatment options, including dry eye treatment devices. The availability advanced technologies such as intense pulsed light (IPL), meibomian gland expression (MGX), and combination therapies drives the product demand in the region.
 

North America has a robust healthcare system with well-established ophthalmology clinics and eye care centers. These facilities offer specialized care for dry eye disease and have access to a wide range of dry eye treatment devices. The availability of insurance coverage for dry eye treatment devices makes them more accessible and affordable for patients, leading to increased demand. The ongoing efforts in research and clinical trials foster innovation and advancements in treatment options, driving the market demand in North America. Therefore, high prevalence of dry eye disease, technological advancements, specialized healthcare infrastructure, increased awareness, insurance coverage, and active R&D activities contribute to the increasing demand for dry eye treatment devices in North America.
 

Dry Eye Treatment Devices Market Share

Some of the major players operating in the dry eye treatment devices market are :

• Alcon, Allergan (AbbVie)
• BioTissue, Inc
• BlephEx LLC
• ESW Vision
• EyePrint Prosthetics, LLC
• Holbar Medical Products
• Johnson & Johnson Vision
• Lumenis
• Mibo Medical Group
• NuSight Medical,
• Sight Sciences

 These leading market players are implementing advanced technologies to cater to the large unmet needs of the consumers. These players focus on strategic partnerships, new product launch & commercialization for market expansion. Furthermore, these players are heavily investing in research that allows them to introduce innovative products.
 

Dry Eye Treatment Devices Industry Leaders:

• In April 2022, Alcon announced the launch of Systane iLux2 a meibomian gland dysfunction (MGD) thermal pulsation system. The Systane iLux2 MGD thermal pulsation system is integrated with advance imaging technology to view both meibomian glands and allows practitioners to tailor MGD treatment in 8-12 minutes. This innovative product launch helped the company to enhance their dry eye treatment devices product portfolio and enhance their business revenue.
   
• In April 2021, Lumenis Ltd. announced that they had received the U.S. FDA approval to launch their OptiLight IPL device for the diagnosis and treatment of dry eye disease. OptiLight is integrated with OPT technology, and offers a consistent, precise, and controlled light-based treatment for dry eye disease. This regulatory approval helped the company to expand their customer base and gain a competitive edge over its peers.
   

Dry eye treatment devices market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue (USD Million) from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

By Technology

• Broadband light (BBL)
• Intense Pulsed Light (IPL)
• Meibomian Gland Expression (MGX)
• Combination (MGX+IPL)

By End-use

• Hospitals
• Ophthalmic Clinics
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Sweden
  • The Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Indonesia
  • Thailand
  • Philippines
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
  • Peru
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Egypt
  • Turkey